Categories

News

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
2026-11-09
Trump’s two‑sided MFN drug pricing policy ties some US drug prices to wealthy‑nation benchmarks while pressuring Europe to lift low prices, a popular policy across party lines. The policy reshapes launch strategies: EU drug launches dropped ~35% post the 2025 executive order, with firms delaying European rollouts or demanding US‑aligned prices to shield US revenue. US list prices still rose, though Medicaid saw net price reductions.
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
2026-11-03
Fresenius signed the biosimilars industry’s‑largest‑ever exclusive development deal with WuXi Biologics on Nov 2, aiming to expand its biosimilar pipeline from 29 to up to 66 candidates over a decade, targeting originator drugs worth over €370‑billion in list‑price salesFresenius .... Fresenius picks projects based on market attractiveness, risk and projected returns, paying WuXi Biologics via fee‑for‑service only for selected candidates.
What real-world data shows about current cancer care
2026-10-29
Clinical trials are the gold standard of medical research, yet only about 5% of adult cancer patients enroll, leaving clinicians short of evidence for diverse real‑world patients. Real‑world data (RWD) has become a key complement. RWD has expanded from claims and pharmacy data to EHRs, genomics, PROs and wearable data. AI and LLMs help process unstructured records. Fueled by the 21st Century Cures Act, FDA accepts real‑world evidence (RWE) to support drug approvals across the drug development
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
2026-10-20
Roche expands its partnership roster with Chinese drugmakers and seals a major ADC collaboration with Hansoh Pharma with a $400 million upfront payment to bolster its oncology pipeline. Roche provides cancer targets while Hansoh uses its antibody-drug conjugate platform to advance therapies through global Phase Ia trials. Roche will take over subsequent development outside Greater China. This piece also reviews selected licensing deals between global pharma and Chinese biotechs from 2025 to 2026
Digital pathology’s next act: Mining old tissue to spare future animal studies
2026-10-09
The pandemic turned digital pathology into an essential tool for remote slide reading. Digitized tissue slides can be combined with pathology reports and molecular data to train AI models, identify tissue molecular patterns and maximize insights from archived animal study samples.
China in Global Clinical Development: Why Early Inclusion Matters
2026-09-03
Many global biotech companies view China as a post-hoc commercial market, considering the country only in later stages of clinical development. This common oversight often forces costly bridging studies, extends development timelines and leaves much of China's R&D potential untapped. 
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
2026-09-02
A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body.
Go to page
CONTACT US
Name *
Email *
Message *
Verification code *
Click to verify